Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6964854 | 0.99 | LMNA (0.51) | LMNASMN1; SMN2HRH1ALDH1A1CHRM2 | |
| SCHEMBL6968455 | 0.89 | SIGMAR1 (0.53) | LMNASMN1; SMN2HRH1ALDH1A1CHRM2 | |
| SCHEMBL6970479 | 0.89 | HRH1 (0.41) | LMNASMN1; SMN2HRH1ALDH1A1CHRM2 | |
| Hydrochloric Acid SCHEMBL6971970 | 0.88 | LMNA (0.52) | LMNASMN1; SMN2HRH1ALDH1A1CHRM2 | |
| Hydrochloric Acid SCHEMBL6964105 | 0.88 | LMNA (0.41) | LMNASMN1; SMN2HRH1ALDH1A1CHRM2 | |
| SCHEMBL6957114 | 0.87 | SLC6A1 (0.44) | LMNASMN1; SMN2HRH1ALDH1A1CHRM2 | |
| SCHEMBL6963106 | 0.87 | SLC6A1 (0.44) | LMNASMN1; SMN2HRH1ALDH1A1CHRM2 | |
| Hydrochloric Acid SCHEMBL6957875 | 0.86 | LMNA (0.45) | LMNASMN1; SMN2HRH1ALDH1A1CHRM2 | |
| Hydrochloric Acid SCHEMBL6958333 | 0.86 | LMNA (0.45) | LMNASMN1; SMN2HRH1ALDH1A1CHRM2 | |
| Oxalic Acid SCHEMBL6970867 | 0.85 | KDM4E (0.47) | LMNASMN1; SMN2HRH1ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934313-B1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK AS (DK) | 2003-05-14 | — | — | EP | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | claimed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| US-6004983-A | ANALGESICS; ANTIINFLAMMATORY, ANTIARTHRITIC AND ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DE) | 1999-12-21 | — | — | US | claimed |
| EP-0934313-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | claimed |
| WO-1998015549-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | disclosed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
| US-6004983-A | ANALGESICS; ANTIINFLAMMATORY, ANTIARTHRITIC AND ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DE) | 1999-12-21 | — | — | US | disclosed |
| EP-0934313-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015549-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | LMNA 3961/4885SMN1; SMN2 1377/4885HRH1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.